Policy | July 03, 2022
Time to move from ‘Volume’ to ‘Value’ leadership to capture global market, says Mandaviya
Govt committed to supporting pharma companies with industry-friendly policies
Govt committed to supporting pharma companies with industry-friendly policies
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
First and only PARP inhibitor to improve invasive disease-free survival in patients
Subscribe To Our Newsletter & Stay Updated
